Background {#Sec1}
==========

It is well known that *Klebsiella pneumoniae* is ubiquitous in nature, one of the most relevant opportunistic pathogens, and causes various human infections such as bloodstream infection (BSI), urinary tract infection (UTI), surgical-site infection, and pneumonia \[[@CR1]--[@CR3]\]. Resistance can develop in *K. pneumoniae* isolates, notably producing extended-spectrum β-lactamases (ESBLs). ESBL-producing strains of *K. pneumoniae* are currently found throughout the world and have caused numerous outbreaks of infection \[[@CR4], [@CR5]\]. Carbapenems represent the first-line therapy for severe infection by ESBL-producing *K. pneumoniae* \[[@CR6]\]. However, since Yigit et al. \[[@CR7], [@CR8]\] reported the first *K. pneumoniae* carbapenem (KPC)-producing *K. pneumoniae* isolate in North Carolina in 1996, carbapenem-resistant strains have increased rapidly, rising from 1.6 to 10.4% associated with central line blood-stream infections between 2001 and 2011 in the United States, and have aroused widespread attention, presenting a challenge because the antimicrobial treatment options remain very restricted \[[@CR7], [@CR9]\].

Carbapenem-resistant *K. pneumoniae* (CRKP) deactivates the carbapenems through two main mechanisms: (1) acquisition of carbapenemase genes that encode for enzymes capable of hydrolyzing carbapenems---the three most important carbapenemase types being KPC-type enzymes, metallo-β-lactamases (VIM, IMP, NDM), and OXA-48 type enzymes; and (2) reduction in the accumulation of antibiotics by a quantitative and/or qualitative deficiency of porin expression in combination with overexpression of β-lactamases that possess weak affinity for carbapenems \[[@CR10]\].

Most researchers reported higher mortality rates among persons infected with CRKP isolates \[[@CR11]--[@CR30]\] while others reported contrary results \[[@CR31], [@CR32]\]. In recent years, many studies from single medical centers or individual countries have reported mortality rates in patients infected with CRKP, but until now there has been no systematic review focusing on mortality resulting from carbapenem-resistant infections in general. Although in a recent meta-analysis Falagas et al. \[[@CR33]\] reported a higher all-cause mortality among patients infected with carbapenem-resistant Enterobacteriaceae than in those with carbapenem-susceptible infections, but their research included only nine studies. Considering this scenario, we conducted a systematic review and meta-analysis to estimate the mortality of patients infected with CRKP, and analyzed mortality resulting from multiple infection types and patients conditions.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

Two independent examiners (LF.X. and XX.S.) searched entries in the PubMed and EMBASE databases from their inception until December 22, 2015 to identify potentially relevant studies. The search terms included "*Klebsiella pneumoniae*" AND resistance AND ("carbapenem" OR "imipenem" OR "meropenem" OR "ertapenem"). The language was restricted to English.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Studies were considered in accordance with inclusion criteria if articles reported mortality of patients infected with CRKP. Research that focused on children, did not differentiate mortality between infection and colonization, did not define the strains that were carbapenem resistant, and did not present the exact death toll were excluded. In this analysis, carbapenem resistance was defined as resistance to carbapenems such as imipenem, meropenem, and ertapenem, irrespective of susceptibility to other antibiotics.

Assessment of study quality {#Sec5}
---------------------------

The articles were assessed for quality of the cohort or case--control studies included in the systematic analysis according to the Newcastle-Ottawa scale (NOS) score \[[@CR34]\], ranging from 0 to 9. Studies with a NOS score of 5 or greater were included in this analysis.

Data extraction {#Sec6}
---------------

Two independent investigators (LF.X. and XX.S.) extracted information from eligible articles. Divergences were solved by discussion and consultation of the relevant literature. The information extracted from original publications included title, first author, year of publication and experiment, type of study, sample size, characteristics of the study population (mean age, sex, type of infection, mean severity of underlying disease), and crude mortality rates in patients infected with CRKP and carbapenem-susceptible *K. pneumoniae* (CSKP). If articles reported mortality from both infection and colonization, we extracted information only regarding infections.

Statistical analysis {#Sec7}
--------------------

We calculated the pooled odds ratio (OR) and 95% confidence interval (CI) by comparing crude mortality in patients with CRKP with that in patients with CSKP. Between-study heterogeneity was assessed by the χ^2^ test (*p* \< 0.10 was selected to indicate the presence of heterogeneity, in which case a random-effects model was adopted; otherwise a fixed-effects model was applied) and *I* ^2^ test (to assess the degree of heterogeneity) \[[@CR35], [@CR36]\]. We then calculated pooled rates of mortality in patients infected with CRKP, and stratified analyses with respect to geographic location, infection types, carbapenemase types, and patients conditions performed. Freeman--Tukey arcsine transformations were used to stabilize the variances, and after the meta-analysis we transformed the summary estimates and the CI boundaries back to proportions using the sine function \[[@CR37]\]. We used Stata version 12.0 software for all statistical calculations.

Results {#Sec8}
=======

Results of the systematic literature search {#Sec9}
-------------------------------------------

We identified and screened 3168 articles. After exclusion by title and abstract, the remaining 87 articles were subjected to full-text assessment for eligibility. Among these articles, 12 were duplicates, seven did not differentiate between infection- and colonization-related mortality, and six did not report valid data. Ultimately, 62 studies were analyzed based on the inclusion and exclusion criteria (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow diagram of included studies

The basic characteristics of these 62 studies are summarized in Table [1](#Tab1){ref-type="table"} \[[@CR11]--[@CR32], [@CR38]--[@CR77]\]. These articles were published from 1999 to 2015 and the sample size varied across studies, ranging from 7 to 1022. The total number of patients in this systematic review was 4701, of whom 2462 had CRKP infection and the remainder CSKP infection. Among these patients, the reported death was 1018 among the CRKP patients and 398 among the CSKP patients. In the pooled analysis, the overall mortality was 42.14% (95% CI 37.06--47.31) in patients infected with CRKP and 21.16% (95% CI 16.07--26.79) in CSKP patients (Table [2](#Tab2){ref-type="table"}).Table 1Characteristics of the eligible studiesAuthor, yearStudy typeRegion/study yearResistanceCRKP mortality (%)CSKP mortality (%)P valueCarbapenemasesInfection typeICUSOTVardakas (2015) \[[@CR11]\]Retrospective cohort studyGreece 2006.1--2009.10CLSI 201058/80 (72.5)14/24 (58.3)0.19NABSI:44/65800Brizendine (2015) \[[@CR16]\]Retrospective cohort studyUSA 2011.12--2013.10CLSI 201216/157 (10.2)NANANAUTI:16/15700Pouch (2015) \[[@CR12]\]Nested case--control studyUSA  2007.1--2010.12CLSI 20096/20 (30)8/80 (10)0.03NAUTI:6/20020Ny (2015) \[[@CR13]\]Retrospective cohort studyUSA  2011.1--2013.12NA7/48 (14.6)5/48 (10.4)0.76NAUTI:2/2700Girmenia (2015) \[[@CR39]\]Retrospective cohort studyItaly  2010.1--2013.7NA65/112 (58.1)NANANAAny infection:65/1120112Hoxha (2015) \[[@CR14]\]Prospective matched cohort studyItaly  2012.11--2013.7Eucast Guideline30/49 (61)10/49 (20)NANAAny infection:30/4900Cubero (2015) \[[@CR15]\]Retrospective cohort studySpain  2010.10--2012.12EUCAST 20158/20 (40)1/9 (11.1)NANAAny infection:8/2000Chang (2015) \[[@CR40]\]Retrospective studyTaiwan  2012.1--2012.12CLSI 201221/41 (51.2)NANAKPC:6/8Any infection:21/41410Chen (2015) \[[@CR68]\]Retrospective studyTaiwan  2014.4--10NA12/41 (29.3)NANANAAny infection:12/4100Madrigal (2015) \[[@CR66]\]Retrospective studySpain  2014.5--9NA2/5 (40)NANANAAny infection:2/500Bias (2015) \[[@CR70]\]Retrospective, observational cohort studyUSA  --2014.8NA5/30 (16.7)NANANAAny infection:5/30030Katsiari (2015) \[[@CR67]\]Prospective, observational studyGreece  2010.4--2012.3CLSI 201214/32 (43.8)NANAKPC:11/28VIM:3/5BSI:9/16320Maristela Freire (2015) \[[@CR69]\]Retrospective cohort studyBrazil  2009.1--2013.12CLSI 201213/31 (41.9)NANAKPC:13/31BSI:7/11\
UTI:1/10031Brizendine (2015) \[[@CR16]\]Retrospective cohort studyUSA  2006--2012NA4/22 (18)1/64 (1.5)NANAUTI:4/22022Sarah Welch (2015) \[[@CR65]\]Retrospective cohort studyUSANA19/51 (37.3)NANANAPneumonia:19/5100van Duin (2014) \[[@CR16]\]Prospective, multi-center, observational studyUSA  2011.12--2013.3CLSI26/114 (22.8)NANANABSI:5/2600Simkins (2014) \[[@CR17]\]Retrospective case--control studyUSA  2006.1--2010.12NA6/13 (46.2)3/39 (7.7)0.005NAAny infection:6/13013Viviana Gómez Rueda (2014) \[[@CR18]\]Case--case--control studyColombia  2008.1--2011.1CLSI31/61 (50.8)20/61 (32.8)NANAAny infection:31/6100Christoph Lübbert (2014) \[[@CR71]\]Retrospective studyGermany  2010.9--2011.9NA7/8 (87.5)NANAKPC:7/8Any infection:7/808Qureshi (2014) \[[@CR42]\]Retrospective cohort studyUSA  2009.1--2012.10NA0/21 (0.00)NANANAUTI:0/2100Mouloudi (2014) \[[@CR43]\]Retrospective cohort studyGreece  2008.1--2011.12EUCAST 201214/17 (82.4)NANANABSI:14/171717Bulent Aydinl (2014) \[[@CR72]\]Retrospective analysisTurkey  2012.1--2013.11NA2/5 (40)NANANAAny infection:2/505Gallagher (2014) \[[@CR44]\]Retrospective case--case--control studyUSA  2005.6--2010.10CLSI 200919/43 (44.2)NANANABSI:19/4300Graziella Hanna Pereira (2013) \[[@CR47]\]Retrospective cohort studyBrazil  2008.10--2010.10CLSI 201016/33 (48)NANANABSI:9/11\
UTI:3/21\
Pneumonia:3/700Orsi (2013) \[[@CR19]\]Case--case--control studyItaly  2008.7--2011.6EUCAST25/65 (38.5)12/43 (27.9)NAKPC:14/36Any infection:25/6500Kontopidou (2013) \[[@CR48]\]Retrospective cohort studyGreece  2009.9--2010.6CLSI 201029/127 (22.8)NANANAAny infection:29/1271270Hussein (2013) \[[@CR20]\]Retrospective case control studyIsrael  2006.1--2008.12CLSI 200645/103 (43.7)62/214 (29)NANABSI:45/10300Luci Correa (2013) \[[@CR22]\]Matched case--control studyBrazil  2006.1--2008.8CLSI 200910/20 (50)11/40 (27.5)0.085NAAny infection:10/2000Clancy (2013) \[[@CR49]\]Single-center, retrospective studyUSA  2008.8--2011.7CLSI 20123/17 (17.6)NANANABSI:3/17017Cober (2013) \[[@CR21]\]Retrospective cohort studyUSA  2006--2009NA8/19 (42.1)7/460.005NABSI:8/19019Grossi (2013) \[[@CR73]\]Retrospective cohort studyItaly  2009.1--2012.10NA11/36 (30.6)NANANAAny infection:11/36036Cicora (2013) \[[@CR50]\]Observational, retrospective studyArgentina  2011.4--2012.6CLSI 20102/6 (33.3)NANAKPC:2/6UTI:2/606Paola Di Carlo (2013) \[[@CR46]\]Prospective case series studyItaly  2011,8--2012.8EUCAST12/30 (40)NANAKPC:12/30Any infection:12/30300Fligou (2013) \[[@CR88]\]Retrospective cohort studyGreeceCLSI21/48 (43.8)NANAKPC:21/48BSI:21/48480Rose (2012) \[[@CR74]\]Retrospective, cohort studyUSA  2006--2011NA20/44 (45.5)NANANABSI:20/4400Sanchez-Romero (2012) \[[@CR51]\]Retrospective cohort studySpain  2009.1--2009.12CLSI 201113/28 (46.4)NANAVIM:13/28Any infection:13/28280Liu (2012) \[[@CR23]\]Matched case--control studyTaiwan  2007.1--2009.12CLSI 200915/25 (60)20/500.102NABSI:15/2500Kalpoe (2012) \[[@CR52]\]Retrospective cohort studyUSA  2005.1--2006.10NA10/14 (71.4)NANANAAny infection:10/14014Borer (2012) \[[@CR53]\]Retrospective case control studyIsrael  2007.5--2010.1CLSI 200613/42 (31)NANANAAny infection:13/4200Bergamasco (2012) \[[@CR54]\]Retrospective cohort studyBrazil  2009.7--2010.2CLSI 20095/12 (41.7)NANAKPC:2/12Any infection:5/12012Ben-David (2012) \[[@CR24]\]Retrospective cohort studyIsrael  2006.1--2006.12CLSI 200629/42 (69.1)45/150 (30)\<0.001NABSI:29/4200Balkhy (2012) \[[@CR55]\]Retrospective/prospective surveillance studySaudi Arabia  2009.9--2010.8CLSI 20098/20 (40)NANANAAny infection:8/2000Jason Gallagher (2011) \[[@CR75]\]A retrospective, cohort studyUSA  2006--2011NA24/44 (54.5)NANANABSI:24/4400Pereira (2011) \[[@CR56]\]Retrospective cohort studyBrazil  2008.10--2010.8CLSI 20109/22 (40.9)NANANAAny infection:9/2200Orsi (2011) \[[@CR25]\]Retrospective case control studyItaly  2008.7--2009.12EUCAST11/28 (39.3)12/43NANAAny infection:11/2800Neuner (2011) \[[@CR57]\]Retrospective cohort studyUSA  2007.1--2009.5CLSI 200935/60 (58.3)NANANABSI:35/6000Diana Gaviria (2011) \[[@CR31]\]Retrospective matched case--control studyUSA  2009.4--2011.12CLSI1/19 (5.3)3/38 (7.9)NANAAny infection:1/1900Cuzon (2011) \[[@CR59]\]Retrospective cohort studyFrance  2010.4--2010.6CLSI 20105/7 (71.4)NANANAAny infection:5/700Elisa Maria Beirão (2011) \[[@CR58]\]Retrospective cohort studyBrazil  2008.1--2008.12CLSI 20093/6 (50)NANAKPC:3/6Any infection:3/600Nguyen (2010) \[[@CR60]\]Retrospective cohort studyUSA  2004.1--2008.9CLSI29/48 (60.4)NANANABSI:29/4800Vardakas (2010) \[[@CR76]\]Retrospective cohort studyGreece  2006.1--2009.9NA42/56 (75)NANANAAny infection:42/56560Mouloudi (2010) \[[@CR26]\]Retrospective nested case--control studyGreece  2007.1--2008.12CLSI 200725/37 (67.6)9/22 (40.9)0.03KPC: 15/19\
VIM:10/18BSI:25/3700Gregory (2010) \[[@CR61]\]Retrospective case--control studyPuerto Rico  2008.2--2008.9CLSI 20097/19 (36.8)NANANAAny infection:7/1900Balandin Moreno (2010) \[[@CR77]\]Retrospective cohort studySpain  2009.7--2010.4NA2/8 (25)NANAVIM:2/8Any infection:2/880Gasink (2009) \[[@CR27]\]Case--control studyUSA  2006.10--2008.4NA18/56 (32.1)85/863 (9.8)NAKPC:18/56Any infection:18/5600Daikos (2009) \[[@CR28]\]Prospective observational studyGreece  2005.2--2006.3CLSI 20046/14 (42.9)25/148 (16.9)NAVIM:6/14BSI:6/1400Borer (2009) \[[@CR62]\]Matched retrospective, historical cohort studyIsrael  2005.10--2008.10CLSI 200630/64 (46.9)NANANABSI:23/3200Schwaber (2008) \[[@CR29]\]Retrospective cohort studyIsrael  2003--2006CLSI 200521/48 (43.8)7/56 (12.5)NANAAny infection:21/4800Patel (2008) \[[@CR30]\]Retrospective matched case--controlUSA  2004.7--2006.6CLSI 200648/99 (48.5)20/99 (20.2)\<0.001NAAny infection:48/9900Falagas (2007) \[[@CR32]\]Retrospective matched case--control studyGreece  2000.10--2006.5NA16/53 (30.2)18/53 (34)0.83NAAny infection:16/5300Woodford (2004) \[[@CR63]\]Retrospective cohort studyUSA  2000.4--2001.4CLSI8/14 (57.1)NANAKPC:8/14Any infection:8/14140Muhammad Ahmad. (1999) \[[@CR64]\]Retrospective cohort studyUSA  1994.12--1995.11CLSI 19946/8 (75)NANANAAny infection:6/880*CLSI* Clinical and Laboratory Standards Institute, *CRKP* carbapenem-resistant *K. pneumoniae*, *CSKP* carbapenem-susceptible *K. pneumonia*, *BSI* bloodstream infection, *UTI* urinary tract infection Table 2Mortality of patients based on patient condition, carbapenemases type, study regionSubgroupNumber of studiesSample sizeMortality Rate %(95% CI)Statistical modelPooled mortalityP \< 0.001 CRKP62246242.14 (37.06--47.31)Random CSKP22223921.12 (16.07--26.79)RandomPatient conditionsP \< 0.001 Bloodstream infections2072254.30 (47.51--61.02)Random Urinary tract infections828413.52 (7.50--20.92)Random Intensive care unit1247953.90 (39.44--68.00)Random Solid organ transplantation1536243.13 (32.40--54.16)RandomCarbapenemases typeP = 0.645 KPC-producing *Klebsiella pneumoniae*1330247.66 (38.61--49.51)Random VIM-producing *Klebsiella pneumoniae*57346.71 (35.81--57.73)RandomRegionP = 0.062 North America2398033.24 (25.08--42.00)Random South America819146.71 (39.83--53.66)Fixed Europe2186050.06 (41.45--58.62)Random Asia1043144.82 (37.83--51.91)Random*CRKP* Carbapenem-resistant *K. pneumoniae*, *CSKP* carbapenem-susceptible *K. pneumonia*

Comparison of mortality in CRKP and CSKP patients {#Sec10}
-------------------------------------------------

Among the included articles, 22 compared mortality between patients infected with CRKP and CSKP. The summary estimate of these studies from the random-effects model suggested that patients with CRKP had a significantly higher mortality than those with CSKP in the univariate analysis (pooled crude OR 2.80; 95% CI 2.15--3.65) with a moderate heterogeneity *I* ^2^ of 33.9% (*p* = 0.031) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Crude odds ratio (OR) for the association between carbapenem resistance and mortality of patients with *K. pneumoniae* infection

Mortality in multiple patient conditions {#Sec11}
----------------------------------------

As shown in Table [2](#Tab2){ref-type="table"}, 722 patients had BSI and 284 had UTI, 479 were in an intensive care unit (ICU), and 362 underwent solid organ transplantation (SOT). In the pooled analysis, the mortality was 54.30% (95% CI 47.51--61.02), 13.52% (95% CI 7.50--20.92), 48.9% (95% CI 44.47--53.46), and 43.13% (95% CI 32.40--54.16) in BSI, UTI, ICU-admission, and SOT patients, respectively.

Mortality in multiple carbapenemase types {#Sec12}
-----------------------------------------

In this subgroup analysis, we mainly analyzed the mortality of patients infected with KPC-producing *K. pneumoniae* and VIM-producing *K. pneumoniae.* In the articles included, 302 patients were infected with KPC-producing *K. pneumoniae* and 73 were infected with VIM-producing *K. pneumoniae*. The mortality among these two types of carbapenemases was 47.66% (95% CI 38.61--56.79) and 46.71% (95% CI 35.81--57.73), respectively (Table [2](#Tab2){ref-type="table"}).

Mortality in different geographic locations {#Sec13}
-------------------------------------------

Twenty-three studies were carried out in North America, eight in South America, twenty-one in Europe, and ten in Asia. The rate of mortality was 33.24% (95% CI 25.08--42.00) of 980 patients in North America, 46.71% (95% CI 39.83--53.66) of 191 in South America, 50.06% (95% CI 41.45--58.62) of 860 in Europe, and 44.82% (95% CI 37.83--51.91) of 431 in Asia (Table [2](#Tab2){ref-type="table"}).

Discussion {#Sec14}
==========

ESBL-producing *K. pneumoniae* as an opportunistic pathogen is becoming more challenging to treat because of the emergence of carbapenem resistance, and has a significant influence on patient mortality. The primary result of this analysis was the pooled crude mortality of 42.14% among patients with CRKP, which is intimately connected with patients' health and physical status.

Although it is accepted that drug resistance is associated with increased mortality because patients tend to receive inappropriate empiric therapy in general \[[@CR4], [@CR78]\], other studies have found no such relationship. Bhavnani et al. \[[@CR79]\] reported that clinical success was similar between patients with ESBL and those with non-ESBL-producing *K. pneumoniae*, and ESBL production alone did not appear to be an independent risk factor for treatment failure. Kim et al. \[[@CR80]\] also found that ESBL production was not significantly associated with death. In addition, García-Sureda et al. \[[@CR81]\] reported that CRKP isolates are less virulent and fit than CSKP isolates in an antibiotic-free environment. We conducted this systematic review and meta-analysis to estimate the mortality of patients infected with CRKP in general and to study the factors related to mortality resulting from this infection. We found that patients infected with CRKP had significantly higher mortality in comparison with CSKP (crude OR 2.80). To identify risk factors associated with the higher mortality of CRKP infections, we conducted a stratified analysis of patient condition, carbapenemase types, and study location.

Based on multiple patient conditions, our analysis confirmed that patients with CRKP in association with BSI, ICU admission, or SOT have a higher mortality than the pooled mortality, although UTI patients have a lower mortality than the pooled overall mortality, even lower than that of CSKP patients. From this result, we assumed that patient survival has a close relationship with patients' underlying illness and comorbidities. Mouloudi et al. \[[@CR26]\] reported that BSI, ICU admission, and recent receipt of a SOT were associated with ICU and in-hospital mortality in patients infected with CRKP. In addition, patients who had undergone organ transplantation or ICU admission were always subjected to surgical procedures, prolonged ICU stay, preexisting immunosuppression, and the use of invasive devices, which contributed to patients' poor physical condition and resultant higher mortality. In contrast, Daikos et al. suggested that UTI is a relatively mild infection that has only a slight influence on the general condition of patients, and carries a low mortality in general \[[@CR25]\]. It has been shown that factors such as underlying illness and comorbidities have a more important influence on mortality than appropriate empiric treatment with multidrug-resistant Gram-negative bacteria \[[@CR82]\]. Although the underlying patient's condition is important for the outcome of such patients, meanwhile a timely effective treatment can also help to improve the survival rate. Patients in a poor state of health with CRKP were subjected to pathogens longer compared to CSKP infection due to lack of an effective therapy, ultimately, led to a higher mortality.

In the present analysis, patients infected with KPC-producing *K. pneumoniae* have a higher mortality than pooled overall mortality (47.66 vs 42.14%). This result may contribute to KPC-producing *K. pneumoniae* having stronger invasiveness, and the KPC-encoding *blaKPC* always carry other drug-resistant genes, leading to a pronounced drug resistant \[[@CR83]\]. Previous studies have demonstrated *K. pneumoniae*-encoding *blaKPC* to be an independent risk factor in patient mortality \[[@CR26], [@CR27]\]. In addition, KPC-producing *K. pneumoniae* is considered a successful pathogen because of its ability to persist and spread, causing nosocomial outbreaks. Bratu et al. \[[@CR84]\] reported that KPC-producing *K. pneumoniae* isolates are resistant to not only all β-lactam antimicrobials but also frequently other classes of antimicrobials, such as aminoglycosides and fluoroquinolones. In this systematic review, the patients from North America have lower mortality in comparison with the other three locations. This phenomenon may be attributed to a higher level of medical care and different treatment methods in North America, such as combination antibiotics, treatment with polymyxins and tigecycline, and adjunctive procedures (e.g., catheter removal, drainage, or debridement). There is evidence that tigecycline and polymyxins have activity against many CRKP isolates in vitro, and there have been cases reported of successful treatment of CRKP infection with polymyxins and tigecycline \[[@CR85]--[@CR87]\]. Patel et al. \[[@CR30]\] also reported that removal of the focus of infection (i.e., debridement) was independently associated with patient survival.

There are several limitations to this analysis. First, as the included studies reported only unadjusted data on mortality, we analyzed only crude mortality among patients with CRKP. Second, most studies may have lacked power in differentiating death caused by CRKP from any other factors, and it is difficult to draw definitive conclusions from current evidence because of the residual confounding factors and small sample sizes in many studies. Third, some studies included in our meta-analysis did not define a cutoff value to judge the susceptibility of *K. pneumoniae* to carbapenems, and when defined the cutoff value varied among studies owing to different reference criteria. Thus, there exists the potential for heterogeneity. Fourth, most studies were retrospective in nature and thus susceptible to selection bias. Last, we selected only English-language articles, thus limiting the scope of our analysis.

Conclusions {#Sec15}
===========

Our study suggests that patients infected with CRKP have a higher mortality than those infected with CSKP, especially patients with BSI, ICU admission, or SOT intervention. We suggest that the survival of patients has a close relationship with their physical condition. Thus, our results imply that attention should be paid to CRKP infection in patients in a poor state of health, and that strict infection control measures and new antibiotics are required to protect against CRKP infection.

CRKP

:   carbapenem-resistant *Klebsiella pneumoniae*

CSKP

:   carbapenem-suscepyible *Klebsiella pneumoniae*

BSI

:   bloodstream infection

UTI

:   urinary tract infection

ICU

:   intensive care unit

SOT

:   solid organ transplantation
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